How do you incorporate surveillance imaging for patients with ovarian cancer on maintenance therapy?
Does your strategy differ if the patient is on maintenance PARP inhibitor, bevacizumab, both, or neither?
Answer from: at Academic Institution
I typically follow the NCCN guidelines for monitoring/follow up:
Visit every 3 months for 2 years, then every 3-6 months for 3 years, then yearly after year 5.
CA125 (or other tumor markers) at each visit if initially elevated (with the understanding that CA125 monitoring does not affect surviva...
Sign in or Register to read more